Answers are grounded in this paper and cite their sources.
The pharmaceutical industry has paid more attention to potential variability in depressed patients' ability to benefit from antidepressants vs. placebo than psychotherapy researchers have when comparing more to less intensive psychosocial treatments. DeRubeis et al. (2014) introduced the "patient response pattern" (PRP) as part of a quantitative framework to model variability in patients' abilities to benefit from a psychosocial treatment. We extend this framework to examine the influence of PRP on the effect size of a comparison of two mechanistically similar psychosocial treatments. We simulated combinations of "stronger" and "weaker" treatments, crossed with different PRP distributions. Despite modeling a maximum standardized mean difference (SMD) of approximately 1.0, which is considered a large treatment effect, the simulation of a case mix intended to most closely model psychotherapy clinical trials resulted in an SMD of 0.22. Thus, different distributions of PRP can have a substantial effect on the ability to detect differences in the effectiveness of two treatments. Psychotherapy researchers should investigate the influence of heterogeneity in PRP distributions on the results of psychosocial treatment comparisons, and continue to investigate the possibility of using prediction of PRP (e.g., prognostic indicators) for risk stratification and tailored treatment development.
No takes yet. Share an insight, caveat, or question.
Gelfand et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: